4.1 Article

Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX

Journal

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.plefa.2005.05.003

Keywords

-

Funding

  1. NIDCR NIH HHS [P50-DE016191] Funding Source: Medline
  2. NIGMS NIH HHS [GM38765] Funding Source: Medline
  3. PHS HHS [R01-074448] Funding Source: Medline

Ask authors/readers for more resources

Endogenous chemical mediators or autacoids play key roles in controlling inflammation and its programmed resolution. Among them, it is known that lipoxins (LX) and aspirin-triggered LX (ATL) evoke bioactions in a range of physiologic and pathophysiologic processes and serve as endogenous lipid/chemical mediators that stop neutrophilic infiltration and initiate resolution. LXA(4), ATL and their metabolic stable analogs elicit cellular responses and regulate PMN in vivo via interacting with their specific receptor, namely ALX ALX is the first cloned and identified lipoxygenase-derived eicosanoid receptor with cell type-specific signaling pathways. Also, ALX could regulate PMN by interacting with each class of ligands (lipid vs. peptide) within specific phases of an inflammatory response. Together LX, ATL and ALX may provide new opportunities to design resolution-targeted therapies with high degree of precision in controlling inflammation. In this chapter, we give an overview and update of the current actions for LX and ATL, the identification of ALX and their novel anti-inflammatory and pro-resolving signals. (c) 2005 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available